Egetis Therapeutics
4,91 SEK -2,58%2 investorer følger denne virksomhed
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
EGTX
Daglig lav / høj pris
4,865 / 5,11
SEK
Markedsværdi
1,44 mia. SEK
Aktieomsætning
1,13 mio. SEK
Volumen
228 t
Seneste videoer
Finanskalender
Delårsrapport
08.11.2024
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Frazier Life Sciences | 13,2 % | 13,2 % |
| Peder Walberg | 11,5 % | 11,5 % |
| Peter Lindell och bolag | 10,3 % | 10,3 % |
| Fjärde AP-Fonden | 7,3 % | 7,3 % |
| Avla Holding AB | 6,0 % | 6,0 % |
| Handelsbanken Fonder | 4,0 % | 4,0 % |
| RegulaPharm AB | 3,6 % | 3,6 % |
| Unionen | 3,6 % | 3,6 % |
| Linc AB | 2,6 % | 2,6 % |
| Flerie Invest AB | 2,5 % | 2,5 % |
ViserAlle indholdstyper
New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency
Redeye: Egetis Therapeutics Q2 - Eventful quarter
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Interim report Q2 2024
New data shows tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefits
Egetis submits responses to the European Medicines Agency’s Day 120 List of Questions for the Marketing Authorisation Application for tiratricol (Emcitate®)
European Thyroid Association recommends tiratricol (Emcitate®) as long-term therapy for all patients with MCT8 deficiency in new guidelines
